{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T04:40:08Z","timestamp":1720759208911},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,4,28]],"date-time":"2013-04-28T00:00:00Z","timestamp":1367107200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s00063-013-0243-1","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T09:33:29Z","timestamp":1367400809000},"page":"325-336","source":"Crossref","is-referenced-by-count":7,"title":["Antikoagulation"],"prefix":"10.1007","volume":"108","author":[{"given":"B.","family":"P\u00f6tzsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,28]]},"reference":[{"key":"243_CR1","doi-asserted-by":"crossref","unstructured":"Alban S (2007) Kohlenhydrate III: Aminoglykane und Glykosaminoglykane. In: H\u00e4nsel R, Sticher O (Hrsg) Pharmakognosie \u2013 Phytopharmazie. Springer, Berlin Heidelberg New York Tokio, S\u00a0655\u2013704","DOI":"10.1007\/978-3-540-34281-6_20"},{"key":"243_CR2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1538-7933.2004.0584a.x","volume":"2","author":"Depassse","year":"2004","unstructured":"Depassse F, Gerotziafas GT, Busson J et al (2004) Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J Thromb Haemost 2:346\u2013348","journal-title":"J Thromb Haemost"},{"key":"243_CR3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrcardio.2012.61","volume":"9","author":"Arsenault","year":"2012","unstructured":"Arsenault KA, Hirsh J, Whitlock RP et al (2012) Direct thrombin inhibitors in cardiovascular disease. Nat Rev Cardiol 9:402\u2013414","journal-title":"Nat Rev Cardiol"},{"key":"243_CR4","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","volume":"133","author":"Ansell","year":"2008","unstructured":"Ansell J, Hirsh J, Hylek E et al (2008) Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines, 8th edn. Chest 133(6 Suppl):160S\u2013198S","journal-title":"Chest"},{"key":"243_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","volume":"48","author":"Eriksson","year":"2009","unstructured":"Eriksson BI, Quinlan DJ, Weitz JI (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 48:1\u201322","journal-title":"Clin Pharmacokinet"},{"key":"243_CR6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1160\/TH11-06-0391","volume":"107","author":"Samama","year":"2012","unstructured":"Samama MM, Contant G, Spiro TE et al (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:379\u2013387","journal-title":"Thromb Haemost"},{"key":"243_CR7","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","volume":"133","author":"Geerts","year":"2008","unstructured":"Geerts WH, Berquist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines, 8th edn. Chest 133(6 Suppl):381S\u2013453S","journal-title":"Chest"},{"key":"243_CR8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0025-6196(12)60825-8","volume":"67","author":"Mohr","year":"1992","unstructured":"Mohr DN, Silverstein MD, Ilstrup DM et al (1992) Venous thromboembolism associated with hip and knee arthroplasty: current prophylactiv practices and outcomes. Mayo Clin Proc 67:861\u2013870","journal-title":"Mayo Clin Proc"},{"key":"243_CR9","unstructured":"Leitfaden der Arzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4) (2012) Orale Antikoagulation bei nicht valvul\u00e4rem Vorhofflimmern \u2013 Empfehlungen zum Einsatz der neuen Antikoagulantien Dabigatran (Pradaxa\u00ae) und Rivaroxaban (Xarelto\u00ae). Version 1.0"},{"key":"243_CR10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"243_CR11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Gang J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"243_CR12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"243_CR13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.beha.2012.06.003","volume":"25","author":"Schulman","year":"2012","unstructured":"Schulman S (2012) Advances in the management of venous thromboembolism. Best Pract Res Clin Haematol 25:361\u2013377","journal-title":"Best Pract Res Clin Haematol"},{"key":"243_CR14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/ejh.12002","volume":"89","author":"Prandoni","year":"2012","unstructured":"Prandoni P (2012) Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study. Eur J Haematol 89:281\u2013287","journal-title":"Eur J Haematol"},{"key":"243_CR15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccl.2012.04.004","volume":"30","author":"Traill","year":"2012","unstructured":"Traill TA (2012) Valvular heart disease and pregnancy. Cardiol Clin 30:369\u2013381","journal-title":"Cardiol Clin"},{"key":"243_CR16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2012.04630.x","volume":"10","author":"Spyropoulos","year":"2012","unstructured":"Spyropoulos AC, Douketis JD, Gerotziafas G et al (2012) Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost 10:692\u2013694","journal-title":"J Thromb Haemost"},{"key":"243_CR17","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","volume":"124","author":"Eerenberg","year":"2011","unstructured":"Eerenberg ES, Kamphuisen PW, Meertien K et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate \u2013 a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573\u20131579","journal-title":"Circulation"},{"key":"243_CR18","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","volume":"141","author":"Linkins","year":"2012","unstructured":"Linkins LA, Dans AL, Moores LK et al (2012) Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th edn. American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e495S\u2013e530S","journal-title":"Chest"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-013-0243-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00063-013-0243-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-013-0243-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T07:23:50Z","timestamp":1563002630000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00063-013-0243-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,28]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["243"],"URL":"https:\/\/doi.org\/10.1007\/s00063-013-0243-1","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,28]]}}}